Interesting to know that we partnered with Eli Lilly on this, and study has completed Phase 2. JJ has been withholding info from us. Think about all the investor conferences that AEMD has attended, without a blurb about ESI. I can understand he wants to maintain a low profile and not attrack attention, but this is info that investors should know.
News 
Market Data 
Discover 
